307 related articles for article (PubMed ID: 27831830)
41. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.
Li H; Guo Z; Si T; Wang H
Eur J Gastroenterol Hepatol; 2013 May; 25(5):620-7. PubMed ID: 23325276
[TBL] [Abstract][Full Text] [Related]
42. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
43. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy.
Akinwande O; Philips P; Scoggins CR; Kelly L; Tatum C; Hahl M; McMasters KM; Martin RC
J Surg Oncol; 2016 Mar; 113(4):443-8. PubMed ID: 27060707
[TBL] [Abstract][Full Text] [Related]
44. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.
Fleckenstein FN; Schernthaner RE; Duran R; Sohn JH; Sahu S; Zhao Y; Hamm B; Gebauer B; Lin M; Geschwind JF; Chapiro J
Eur Radiol; 2016 Sep; 26(9):3243-52. PubMed ID: 26762942
[TBL] [Abstract][Full Text] [Related]
45. Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads.
Yeo DM; Choi JI; Lee YJ; Park MY; Chun HJ; Lee HG
J Comput Assist Tomogr; 2014; 38(3):391-7. PubMed ID: 24681857
[TBL] [Abstract][Full Text] [Related]
46. Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization.
Duran R; Chapiro J; Frangakis C; Lin M; Schlachter TR; Schernthaner RE; Wang Z; Savic LJ; Tacher V; Kamel IR; Geschwind JF
Transl Oncol; 2014 Aug; 7(4):447-55. PubMed ID: 24953419
[TBL] [Abstract][Full Text] [Related]
47. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival.
Gowdra Halappa V; Corona-Villalobos CP; Bonekamp S; Li Z; Reyes D; Cosgrove D; Pawlik TM; Diaz LA; Bhagat N; Eng J; Geschwind JF; Kamel IR
Radiology; 2013 Feb; 266(2):502-13. PubMed ID: 23192780
[TBL] [Abstract][Full Text] [Related]
48. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses.
Riaz A; Gabr A; Abouchaleh N; Ali R; Al Asadi A; Mora R; Kulik L; Desai K; Thornburg B; Mouli S; Hickey R; Miller FH; Yaghmai V; Ganger D; Lewandowski RJ; Salem R
Hepatology; 2018 Mar; 67(3):873-883. PubMed ID: 28833344
[TBL] [Abstract][Full Text] [Related]
49. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
50. Response Evaluation of Malignant Liver Lesions After TACE/SIRT: Comparison of Manual and Semi-Automatic Measurement of Different Response Criteria in Multislice CT.
Höink AJ; Schülke C; Koch R; Löhnert A; Kammerer S; Fortkamp R; Heindel W; Buerke B
Rofo; 2017 Nov; 189(11):1067-1075. PubMed ID: 28834965
[No Abstract] [Full Text] [Related]
51. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.
Liapi E; Geschwind JF; Vossen JA; Buijs M; Georgiades CS; Bluemke DA; Kamel IR
AJR Am J Roentgenol; 2008 Jan; 190(1):67-73. PubMed ID: 18094295
[TBL] [Abstract][Full Text] [Related]
52. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period.
Gruber-Rouh T; Naguib NN; Eichler K; Ackermann H; Zangos S; Trojan J; Beeres M; Harth M; Schulz B; Nour-Eldin A NE; Vogl TJ
Int J Cancer; 2014 Mar; 134(5):1225-31. PubMed ID: 23960002
[TBL] [Abstract][Full Text] [Related]
53. Quantitative volumetric functional MR imaging: an imaging biomarker of early treatment response in hypo-vascular liver metastasis patients after yttrium-90 transarterial radioembolization.
Zhu X; Sobhani F; Xu C; Pan L; Ghasebeh MA; Kamel IR
Abdom Radiol (NY); 2016 Aug; 41(8):1495-504. PubMed ID: 26960726
[TBL] [Abstract][Full Text] [Related]
54. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma.
Wang D; Gaba RC; Jin B; Lewandowski RJ; Riaz A; Memon K; Ryu RK; Sato KT; Kulik LM; Mulcahy MF; Larson AC; Salem R; Omary RA
Radiology; 2014 Aug; 272(2):587-97. PubMed ID: 24678859
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: feasibility and survival rates.
Vogl TJ; Kreutzträger M; Gruber-Rouh T; Eichler K; Nour-Eldin NE; Zangos S; Naguib NN
Eur J Radiol; 2014 Oct; 83(10):1804-10. PubMed ID: 25082479
[TBL] [Abstract][Full Text] [Related]
56. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response.
Halappa VG; Bonekamp S; Corona-Villalobos CP; Li Z; Mensa M; Reyes D; Eng J; Bhagat N; Pawlik TM; Geschwind JF; Kamel IR
Radiology; 2012 Jul; 264(1):285-94. PubMed ID: 22627601
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Zarghampour M; Khoshpouri P; Ameli S; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Oct; 29(10):5160-5171. PubMed ID: 30877462
[TBL] [Abstract][Full Text] [Related]
58. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.
Vincenzi B; Di Maio M; Silletta M; D'Onofrio L; Spoto C; Piccirillo MC; Daniele G; Comito F; Maci E; Bronte G; Russo A; Santini D; Perrone F; Tonini G
PLoS One; 2015; 10(7):e0133488. PubMed ID: 26230853
[TBL] [Abstract][Full Text] [Related]
59. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
[TBL] [Abstract][Full Text] [Related]
60. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
Lee JS; Choi HJ; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baek SE; Chung YE; Park MS; Kim MJ; Rhee H; Kim SU
Gut Liver; 2020 Nov; 14(6):765-774. PubMed ID: 32050313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
